Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) found that larotrectinib, ...

In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.

It also recommended approval for the treatment of certain adult and pediatric patients aged 12 years and older with advanced solid tumors expressing a NTRK gene fusion, according to a statement.

The new indication puts Augtyro in contention with other therapies for NTRK gene fusion cancers, including Rozlytrek (entrectinib) and Bayer’s Vitrakvi (larotrectinib), which were approved for ...

The EU drugs regulator cleared Vitrakvi (larotrectinib) for the treatment of patients with solid tumours that have an NTRK gene fusion, are locally advanced, metastatic or for whom surgical ...

Augtyro was recommended as monotherapy for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expressing a NTRK gene fusion and (1) have received a ...

The firm will study ANS03 in patients with tumors harboring a ROS1 or NTRK alteration, including those with acquired resistance mutations.

Neurotrophic tropomyosin receptor kinase (NTRK) are a family of receptors involved in neural development. An NTRK gene fusion is an alteration that occurs when a piece of the chromosome containing the ...